论文部分内容阅读
背景与目的:曲妥珠单抗作用靶点是人表皮生长因子受体-2(Her-2)的细胞外部位,对Her-2过表达的乳腺癌患者疗效肯定,与化疗药物联合应用疗效更好。本研究观察了国产曲妥珠单抗单药或联合诺维本(NVB)治疗转移性乳腺癌的疗效及不良反应。方法:共24例转移性乳癌患者入组,单药组:曲妥珠单抗首次4 mg/kg,以后每周1次,2 mg/kg;联合组:NVB 25 mg/m2d 1、8、15,同时应用曲妥珠单抗,用法同单药组,4周为1个周期。8周、12周、20周和24周时进行疗效评价。结果:可评价疗效的有23例。单药组有效率20.0%(2/10),1例CR、1例PR,SD 30.0%(3/10),PD 50.0%(5/10);联合组有效率为84.6%(11/13),均为PR,SD 7.7%(1/13),PD 7.7%(1/13)。不良反应与曲妥珠单抗有关的:寒战8例、发热11例,皮疹3例,心悸2例,与诺维本有关的主要有乏力7例、手麻7例,麻痹性肠梗阻2例。诺维本引起的Ⅲ、Ⅳ度粒细胞减少为80.0%(12/15)。结论:单药曲妥珠单抗治疗转移性乳腺癌有一定疗效,联合诺维本后有非常好的疗效,不良反应可耐受。
BACKGROUND & OBJECTIVE: Trastuzumab targets the extracellular region of human epidermal growth factor receptor-2 (Her-2), confirms the efficacy of Her-2 overexpression in breast cancer patients and is effective in combination with chemotherapy drugs better. This study looked at the efficacy and adverse reactions of domestic trastuzumab monotherapy or combined with Novobib (NVB) in the treatment of metastatic breast cancer. Methods: A total of 24 patients with metastatic breast cancer were enrolled in the study. The single drug group was given trastuzumab for the first time at 4 mg / kg, once a week afterwards, at 2 mg / kg. The combination group: NVB at 25 mg / m2d 1,8, 15, while trastuzumab, the same method with the monotherapy group, 4 weeks for a cycle. 8 weeks, 12 weeks, 20 weeks and 24 weeks for efficacy evaluation. Results: There are 23 evaluable curative effects. The effective rate was 20.0% (2/10) in single drug group, 1 case of CR, 1 case of PR, SD 30.0% (3/10) and PD 50.0% (5/10) ) Were PR, SD 7.7% (1/13), PD 7.7% (1/13). Adverse reactions associated with trastuzumab: chills in 8 cases, fever in 11 cases, 3 cases of rash, heart palpitations in 2 cases, and novibenzepine main weakness in 7 cases, 7 cases of hand numbness, paralytic ileus in 2 cases . Noviridin caused Ⅲ, Ⅳ degree neutropenia was 80.0% (12/15). Conclusion: The single trastuzumab treatment of metastatic breast cancer have a certain effect, combined with noviroban has a very good curative effect, adverse reactions can be tolerated.